ZENOBIA THERAPEUTICS
Zenobia Therapeutics was founded in 2008 with a focus on discovering treatments for neurodegenerative diseases using fragment-based lead discovery. In 2014, Zenobia added a products division, Zenobia Fragments that supplies products and services to support fragment-based lead discovery.
ZENOBIA THERAPEUTICS
Industry:
Biotechnology Pharmaceutical
Founded:
2008-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.zenobiatherapeutics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
225 K USD
Technology used in webpage:
Google Google Cloud Wix
Similar Organizations
Aclipse Therapeutics
Aclipse Therapeutics focuses on developing differentiated drugs to address diseases with unmet medical needs.
Aperture Therapeutics
Aperture Therapeutics develops novel therapies for neurodegenerative diseases, leveraging genetic diversity.
Lysosomal Therapeutics
Lysosomal Therapeutics deliver cures for neurodegenerative diseases.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Current Employees Featured
Founder
Investors List
National Science Foundation
National Science Foundation investment in Grant - Zenobia Therapeutics
Official Site Inspections
http://www.zenobiatherapeutics.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Zenobia Therapeutics"
Home | Zenobia Therapeutics
[email protected]. 3550 General Atomics Court San Diego, CA 92121 ©2016 BY ZENOBIA THERAPEUTICS. PROUDLY CREATED WITH WIX.COM. bottom of page ...See details»
Zenobia Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Zenobia Therapeutics was founded in 2008 with a focus on discovering treatments for neurodegenerative โฆSee details»
Zenobia Therapeutics, Inc. Company Profile | San Diego, CA ...
Find company research, competitor information, contact details & financial data for Zenobia Therapeutics, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
ZENOBIA THERAPEUTICS Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ZENOBIA THERAPEUTICS of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
Zenobia Therapeutics 2025 Company Profile: Valuation, Funding ...
Zenobia Therapeutics General Information Description. Developer of fragment products intended to treat neurodegenerative diseases. The company's medical treatments use fragment-based โฆSee details»
Zenobia Therapeutics Company Profile | Management and
[email protected]: Zenobia Therapeutics Top Competitors. Company Employees Revenue Top technologies; Structure Based Design Inc. 9: $1.2 M: Creative BioLabs. 36: $4.3 โฆSee details»
Zenobia Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Zenobia Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 9 literature, Drug:G-2019S LRRK2 program (Zenobia Therapeutics).See details»
Zenobia Therapeutics - Craft
Zenobia Therapeutics has 1 employees at their 1 location. See insights on Zenobia Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more โฆSee details»
Zenobia Therapeutics - Overview, News & Similar companies
Zenobia Therapeutics contact info: Phone number: (858) 926-5780 Website: www.zenobiatherapeutics.com What does Zenobia Therapeutics do? Zenobia Therapeutics โฆSee details»
Zenobia Therapeutics - VentureRadar
Website: https://www.zenobiatherapeutics.com/ Offers treatment discovery for neurodegenerative diseases through fragment-based lead discovery, internal CNS research ...See details»
Zenobia Therapeutics - 2025 Company Profile - Tracxn
Mar 5, 2025 Zenobia Therapeutics - Using fragment-based lead discovery to identify small molecules for the treatment of Parkinson's, Huntington's and Alzheimer's disease.. Raised โฆSee details»
Zenobia Therapeutics, Inc. - CMOCRO
Zenobia Therapeutics was founded with a focus on discovering treatments for neurodegenerative diseases using fragment-based lead discovery. Zenobia added a products division, Zenobia โฆSee details»
Zenobia Therapeutics - Products, Competitors, Financials, โฆ
Headquarters Location. 3550 General Atomics Court . San Diego, California, 92121, United States. 619-249-5213See details»
Zenobia Therapeutics Background - zenfragments-copy
Zenobia Fragments is a division of Zenobia Therapeutics founded in 2008 by Dr. Vicki Nienaber and Dr. Robert Meadows. Our focus is 100% on making fragment-based lead discovery a โฆSee details»
Zenobia Therapeutics โ CIRM - California
Program Type Investigator Grant Title Award Value; Inception โ Discovery Stage Research Projects: Vicki Nienaber: A new phenotypic screening platform that identifies biologically โฆSee details»
Zenobia Therapeutics, Inc. (Zenobia Therapeutics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ โฆ
ไบ่งฃZenobia Therapeutics, Inc. (Zenobia Therapeutics, Inc.)ๅ ฌๅธ็่ฏ็ฉ็ฎก็บฟ๏ผๆฒป็้ขๅ๏ผๆๆฏๅนณๅฐ๏ผไปฅๅๅฎ็9็ฏๆ็ฎ๏ผ่ฏ็ฉ:G-2019S LRRK2 program (Zenobia Therapeutics)ใSee details»
Zenobia Therapeutics, Inc. Begins Operations as a ... - Fierce Biotech
Jul 21, 2008 Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company LA JOLLA, Calif., July 21 /PRNewswire/ -- Zenobia Therapeutics, Inc. โฆSee details»
Zenobia Therapeutics Announce A Partnership With The โฆ
LA JOLLA, Calif., Aug. 14, 2012 /PRNewswire/ -- Zenobia Therapeutics, the leader in fragment-based lead discovery for CNS disease announce today a strategic partnership to provide โฆSee details»
Zenobia Therapeutics, Inc. Successfully Completes Initial
LA JOLLA, Calif., April 14 /PRNewswire/ -- Zenobia Therapeutics, Inc., the leader in fragment-based lead discovery for diseases of the central nervous system, announced successful โฆSee details»
Cobenfy: A New Mechanism of Action for the Treatment of โฆ
Mar 21, 2025 Author: Caryssa Drinkuth Editor: Keita Yokoyama. Today, we will be covering Bristol-Myers Squibbโs Cobenfy (xanomeline and trospium chloride). On September 26, 2024, โฆSee details»